Phase II Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer
Latest Information Update: 06 May 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 May 2024 Results for safety and efficacy , published in the International Journal of Radiation Oncology, Biology, Physics
- 10 Jan 2024 Status changed from discontinued to completed.
- 06 Jun 2023 Status changed to discontinued, as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.